VGT-309 for Lung Cancers

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Hospital of the University of Pennsylvania, Philadelphia, PA
Lung Cancers+1 More
VGT-309 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new way to find cancer in people who are having surgery for lung cancer. The drug VGT-309 will be used in this trial to treat patients with lung cancer. This drug has already been approved by the FDA to treat another condition. All patients in this trial will receive the active drug, and there will be no placebo group.

Eligible Conditions

  • Lung Cancers

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: during surgery

During surgery
The proportion of subjects with at least one Clinically Significant Event (CSE)
during surgery
Sensitivity, Specificity, Positive Predictive Value and Negative Predictive Value of VGT-309

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

0.32mg/kg VGT-309
1 of 1
Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: VGT-309 · No Placebo Group · Phase 2

0.32mg/kg VGT-309
Drug
Experimental Group · 1 Intervention: VGT-309 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: during surgery
Closest Location: Hospital of the University of Pennsylvania · Philadelphia, PA
Photo of Philadelphia 1Photo of Philadelphia 2Photo of Philadelphia 3
2002First Recorded Clinical Trial
2 TrialsResearching Lung Cancers
380 CompletedClinical Trials

Who is running the clinical trial?

Vergent Bioscience, Inc.Lead Sponsor
Curt Scribner, MDStudy DirectorVergent Bioscience
1 Previous Clinical Trials
10 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are willing and able to sign the informed consent and comply with study procedures.
You are of childbearing potential and agree to use highly effective contraception from screening through Day 30.
You are scheduled to undergo standard of care surgical resection for a lung nodule or mass with diagnostic and/or curative intent and meet all pre-operative surgical and anesthesia acceptance criteria.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.